ResMed traded at $254.74 this Monday February 2nd, decreasing $3.57 or 1.38 percent since the previous trading session. Looking back, over the last four weeks, ResMed lost 3.82 percent. Over the last 12 months, its price rose by 5.90 percent. Looking ahead, we forecast ResMed to be priced at 250.35 by the end of this quarter and at 227.93 in one year, according to Trading Economics global macro models projections and analysts expectations.
ResMed Inc. is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep apnea, chronic obstructive pulmonary disease (COPD), neuromuscular disease and other chronic diseases. The Company operates through two segments: Sleep and Respiratory Care segment, and the Software-as-a-Service (SaaS) segment. Sleep apnea includes obstructive sleep apnea and other respiratory disorders that occur during sleep. Its cloud-based digital health applications, along with its devices, are designed to provide connected care to improve patient outcomes. The Company's portfolio of products includes ventilation devices, diagnostic products, mask systems, headgear and other accessories, dental devices, portable oxygen concentrators (POCs) and cloud-based software informatics solutions.